이매티닙
|
|
이매티닙 속성
- 녹는점
- 208-210°C (dec.)
- 밀도
- 1?+-.0.06 g/cm3(Predicted)
- 저장 조건
- Keep in dark place,Sealed in dry,Store in freezer, under -20°C
- 용해도
- DMSO (Slightly, Heated), Methanol (Slightly, Heated)
- 산도 계수 (pKa)
- pKa1 8.07; pKa2 3.73; pKa3 2.56; pKa4 1.52(at 25℃)
- 물리적 상태
- 고체
- 물리적 상태
- 단단한 모양
- 색상
- 흰색에서 옅은 베이지까지
- Merck
- 14,4902
- CAS 데이터베이스
- 152459-95-5(CAS DataBase Reference)
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
안전지침서 | 24/25 | ||
---|---|---|---|
RTECS 번호 | CV5585673 | ||
HS 번호 | 29339900 |
이매티닙 C화학적 특성, 용도, 생산
화학적 성질
Orange Solid용도
Imatinib impurity.Indications
Bcr-Abl inhibitor imatinib (Gleevec(R), Novartis) was approved in 2001 by the FDA. Although fasudil was approved in 1995, imatinib is widely perceived as the first approved SMKI mainly owing to the fact that fasudil's kinase inhibitory mechanism was unknown at the time of approval, and efforts to gain approval of fasudil have been unsuccessful in the United States and Europe.The field of kinase inhibitor development has evolved rapidly since the approval of imatinib. Some of the key discoveries and events include (i) the discovery of MAPK/ERK inhibitors, for example, CI-1040 (PD184352), as the first series of type III inhibitors in 2003; (ii) the approval of first dual tyrosine kinase and serine/threonine kinase inhibitor sorafenib in 2005; (iii) the description of the first series of allosteric type IVkinase inhibitor, that is,GNF-2 and analogues that inhibit Bcr–Abl through an allosteric non-ATP-competitivemode, by Gray and coworkers in 2006; (iv) the approval of the first type III inhibitor trametinib in 2013; (v) the approval of the first covalent kinase inhibitors, afatinib and ibrutinib, in 2013; and (vi) the approval of the first lipid kinase inhibitor, that is, the PI3K inhibitor idelalisib, in 2014.
By December 2016, kinase inhibitor drug discovery can leverage the structures of over 200 human kinases and 5000 kinases of all types, over 1 million publications, clinical data from more than 200 molecules currently in phase I–III trials, and post-marketing results from the approved 38 drugs.
이매티닙 준비 용품 및 원자재
원자재
Benzamide, N-(3-bromo-4-methylphenyl)-4-[(4-methyl-1-piperazinyl)methyl]-
Benzoic acid, 4-[(4-methyl-1-piperazinyl)methyl]-, ethyl ester
1-(4-Bromobenzyl)-4-methylpiperazine
4-(4-Methylpiperazin-1-ylmethyl)benzoyl chloride
N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine
METHYL 4-[(4-METHYLPIPERAZIN-1-YL)METHYL]BENZOATE
4-(Pyridin-3-yl)pyrimidin-2-amine
준비 용품
이매티닙 공급 업체
글로벌( 601)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
LEAP CHEM CO., LTD. | +86-852-30606658 |
market18@leapchem.com | China | 24738 | 58 |
Hebei Mojin Biotechnology Co., Ltd | +8613288715578 |
sales@hbmojin.com | China | 12456 | 58 |
Sinoway Industrial co., ltd. | 0592-5800732; +8613806035118 |
xie@china-sinoway.com | China | 992 | 58 |
Nanjing Fred Technology Co., Ltd | +86-25-84696168 +86-15380713688 |
Austin@fredbio.com | China | 2449 | 58 |
Henan Fengda Chemical Co., Ltd | +86-371-86557731 +86-13613820652 |
info@fdachem.com | China | 7786 | 58 |
Capot Chemical Co.,Ltd. | 571-85586718 +8613336195806 |
sales@capotchem.com | China | 29797 | 60 |
Beijing Cooperate Pharmaceutical Co.,Ltd | 010-60279497 |
sales01@cooperate-pharm.com | CHINA | 1811 | 55 |
Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 |
info@tianfuchem.com | China | 21691 | 55 |
Hangzhou FandaChem Co.,Ltd. | 008657128800458; +8615858145714 |
fandachem@gmail.com | China | 9348 | 55 |
Shanghai Yingrui Biopharma Co., Ltd. | +86-21-33585366 - 03@ |
sales03@shyrchem.com | CHINA | 738 | 60 |
이매티닙 관련 검색:
살리실산 메틸 아세트산 메틸 4-아미노피리딘 4-다이메틸아미노피리딘 쿠레톡심메틸 티오판산-메틸 3-아미노피리딘 피리미포스-메틸 브롬화 메틸 메틸 파라싸이온(메틸 파라티온)
Sunitinib
Gefitinib
Tribenuron methyl
METSULFURON METHYL
5-Amino-2-methylpyridine
3,4'-DIAMINODIPHENYLMETHANE
sodium:(2S)-2-[12-ethyl-8-(hydroxymethyl)-9-oxo-2-(4-piperidin-1-ylpiperidine-1-carbonyl)oxy-11H-indolizino[1,2-b]quinolin-7-yl]-2-hydroxybutanoate
N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine